What You Should Know About the Flu - The New York Times
We’ve had two light years in a row, which some experts worry could mean we’ll be in for a rough few months.
Stay updated with breaking news from Fluzone High Dose. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
We’ve had two light years in a row, which some experts worry could mean we’ll be in for a rough few months.
Movies are back at the Beals Memorial LibraryWINCHENDON — Are you looking for something fun to do indoors this month? After a long hiatus, the library will resume its monthly indoor movie series with four different films throughout the month of...
It has more available hospital beds, ventilators, N95 masks, COVID-19 testing capacity, and better contact tracing. And it may be that this year’s flu season is comparatively mild, thanks to a society that has become accustomed to social distancing, frequent hand-washing, and the wearing of masks. It is also hoped that citizens will take advantage of increased flu vaccine availability. But the province is still preparing for a worst-case scenario, which would be a major second wave of COVID-19 converging with a bad flu season. "We're preparing for the challenges that the influenza seaso...
Operator Ladies and gentlemen, thank you for standing by. Welcome to the Sanofi Fourth Quarter 2020 Earnings Call and Virtual Capital Markets Day. We have planned for a 15-minute break between both events. You may remain connected to the Zoom link for all sessions. I would now like to turn the call over to Eva Schaefer-Jansen, Head of Sanofi Investor Relations. Please go ahead, Eva. Eva Schaefer-Jansen -- Head of Investor Relations Good morning, good afternoon and good evening to everyone. Thank you for joining us to review Sanofi's 2020 fourth quarter results, followed by a dedicated Q&A se...
ResearchAndMarkets.com's offering. The seasonal influenza vaccines market in the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK) is expected to continue to expand over the next 10 years, largely due to the continued uptake of premium-priced vaccines in the elderly subgroup, including quadrivalent forms of Fluzone High-Dose (HD) and Fluad, as well as the launch of the first-in-class adjuvanted nanoparticle vaccine, NanoFlu. Further to this, an aging population in the US, Japan, five major European markets, and other developed countries will increase the n...